JFS Wealth Advisors’s Cytokinetics CYTK Stock Holding History

JFS Wealth Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.36K	Buy	16 +4	+33%	+$287	﹤0.01%	1727
2026 Q1	$791	Buy	+12	New	+$763	﹤0.01%	1707
2025 Q2	–	Sell	-8	Closed	-$322	–	1895
2025 Q1	$322	Hold	8	–	–	﹤0.01%	1809
2024 Q4	$377	Sell	8 -34	-81%	-$1.77K	﹤0.01%	1808
2024 Q3	$2.22K	Buy	42 +17	+68%	+$948	﹤0.01%	1439
2024 Q2	$1.35K	Buy	25 +17	+213%	+$1.03K	﹤0.01%	1577
2024 Q1	$561	Hold	8	–	–	﹤0.01%	1768
2023 Q4	$668	Buy	+8	New	+$290	﹤0.01%	1745
2023 Q3	–	Sell	-7	Closed	-$229	–	1974
2023 Q2	$229	Buy	7 +6	+600%	+$222	﹤0.01%	1865
2023 Q1	$36	Buy	+1	New	+$41	﹤0.01%	1934
2022 Q1	–	Sell	-78	Closed	-$4K	–	1850
2021 Q4	$4K	Hold	78	–	–	﹤0.01%	844
2021 Q3	$3K	Buy	+78	New	+$2.3K	﹤0.01%	744

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JFS Wealth Advisors's CYTK Position: Q2 2026 in Review

JFS Wealth Advisors increased its Cytokinetics (CYTK) stake by 33% in Q2 2026, buying an estimated $287 and bringing the position to 16 shares worth $1.36K. The position accounts for ﹤0.01% of the portfolio, ranked #1727.

JFS Wealth Advisors first reported a position in CYTK in Q3 2021 and has held it in 12 quarters since. The position peaked at $4K in Q4 2021. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

JFS Wealth Advisors held 16 shares of Cytokinetics worth $1.36K as of Q2 2026.
JFS Wealth Advisors bought 4 Cytokinetics shares in Q2 2026, an estimated $287.
Cytokinetics made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #1727 holding.
JFS Wealth Advisors first reported a position in Cytokinetics in Q3 2021 and has held it in 12 quarters since.
JFS Wealth Advisors's Cytokinetics position peaked at $4K in Q4 2021.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.